Focal therapy for localized prostate cancer treatment
Official title: A Prospective Registry and Longitudinal Study of Patients Undergoing Focal Therapy for Localized Prostate Cancer
Run by University of California, San Diego · NCT06270043 · Data updated 2026-11-12
This study looks at how well different focal therapy treatments work for men with localized prostate cancer who have chosen this option, by tracking their progress before and after the procedure.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Men only |
| Enrollment | 500 (estimated) |
| Sponsor | University of California, San Diego Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (La Jolla, California) |
| Status | Recruiting |
| Started | February 1, 2024 |
| Main results expected | February 1, 2034 |
| Study ends | February 1, 2034 |
| Registry record updated | February 26, 2024 |
| Trial ID | NCT06270043 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are men with localized prostate cancer who have chosen focal therapy as their treatment option and have a PSA level of 20 or lower.
✕Probably not a fit
Patients who are not candidates for focal therapy or those who require alternative treatments like radical prostatectomy or radiation therapy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to collect and analyze data on the outcomes of prostate cancer patients who have undergone focal therapy. Participants will have already elected or scheduled this treatment method and will be monitored through medical records and questionnaires before and after the procedure. The study seeks to improve patient care by understanding the effectiveness and safety of various focal therapy techniques, including high-intensity frequency ultrasound and cryoablation.
Why it matters
Potential benefit: If successful, this study could enhance treatment options and outcomes for patients with localized prostate cancer.
How similar studies have gone: Other studies have shown promising results with focal therapy approaches for localized prostate cancer, indicating potential for success in this observational study.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject has elected or already undergone focal therapy as their standard of care treatment method and declined alternative treatment (active surveillance, radical prostatectomy, and radiation therapy) * PSA ≤ 20 * Ability to complete informed consent form Exclusion Criteria: * Contraindication to follow-up multi parametric MRI or prostate biopsy * Unable to tolerate general or regional anesthesia
Where it's running
-
University of California, San Diego
La Jolla, California, United States Recruiting
Study contacts
- Study coordinator: Juan Javier-DesLoges, MD
- Email: jjavierdesloges@health.ucsd.edu
- Phone: 858-657-8786
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519
This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.
-
PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer
This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.
-
Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer
This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.
-
Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer
This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.
-
Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence
This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.
-
Lutetium-177 Ludotadipep for advanced prostate cancer
This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.